Insulet Corp.
Company Snapshot
Founded: 2000
Entity Type: Public
Employees: 3,900
Region: U.S.
Revenue: $2,071.6 Millions
Revenue Year: 2024
Segment: Omnipod
Headquarter: Acton, Massachusetts, U.S.
Key Geographics: U.S., China, Malaysia
Corporate Address: 100 Nagog Park, Acton, Massachusetts 01720, U.S. Tel. +1-978-600-7000 www.insulet.com
Company Overview
Insulet Corp. focuses on developing, manufacturing, and selling continuous insulin delivery systems for insulin-dependent diabetes. The company conducts business through two segments- Omnipod Products and Drug Delivery.
The company serves the infusion pump and device market through its Omnipod Products segment. This includes the Omnipod 5 Automated Insulin Delivery System, Omnipod DASH Insulin Management System, Omnipod Insulin Management System, and the latest innovation, Omnipod GO.
The company sells Omnipod products directly to consumers through distribution partners and pharmacies in the U.S. Omnipod products are also available in 25 other countries.
Financial Highlights (FY 2024)
Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***
This information is available for BCC Research members only.
Insulet Corp. In News
Company's Business Segments
- Omnipod : The Omnipod Insulin Management System (“Classic Omnipod”), The Omnipod DASH Insulin Management System (“Omnipod DASH”), and the Omnipod 5 Automated Insulin Delivery System (“Omnipod 5”)
- Drug Delivery : Drug Delivery consists of sales of pods to Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
Applications/End User Industries
- Medicine Manufacturing
- Diabetes
- Patients
- Pharmaceuticals
- Healthcare
BCC Research Beacon 